Which has stronger earnings and valuation, LFST or LMRI?

LifeStance Health Group has higher revenue and earnings than Lumexa Imaging. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeStance Health Group $1.42B 2.36 $9.66M $0.06 144.42 Lumexa Imaging $267.73M 3.29 N/A N/A N/A

Does the media refer more to LFST or LMRI?

In the previous week, LifeStance Health Group had 1 more articles in the media than Lumexa Imaging. MarketBeat recorded 4 mentions for LifeStance Health Group and 3 mentions for Lumexa Imaging. Lumexa Imaging's average media sentiment score of 0.88 beat LifeStance Health Group's score of 0.88 indicating that Lumexa Imaging is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeStance Health Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Lumexa Imaging 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, GRAL or LMRI?

Lumexa Imaging has higher revenue and earnings than GRAIL. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRAIL $147.17M 17.51 -$408.35M -$10.37 N/A Lumexa Imaging $267.73M 3.29 N/A N/A N/A

Is GRAL or LMRI more profitable?

Lumexa Imaging has a net margin of 0.00% compared to GRAIL's net margin of -253.22%. Lumexa Imaging's return on equity of 0.00% beat GRAIL's return on equity. Company Net Margins Return on Equity Return on Assets GRAIL -253.22% -16.42% -14.34% Lumexa Imaging N/A N/A N/A

Does the media favor GRAL or LMRI?

In the previous week, GRAIL had 37 more articles in the media than Lumexa Imaging. MarketBeat recorded 40 mentions for GRAIL and 3 mentions for Lumexa Imaging. Lumexa Imaging's average media sentiment score of 0.88 beat GRAIL's score of 0.01 indicating that Lumexa Imaging is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRAIL 3 Very Positive mention(s) 1 Positive mention(s) 30 Neutral mention(s) 0 Negative mention(s) 5 Very Negative mention(s) Neutral Lumexa Imaging 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, PRVA or LMRI?

Privia Health Group has higher revenue and earnings than Lumexa Imaging. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Privia Health Group $2.12B 1.40 $22.92M $0.16 147.41 Lumexa Imaging $267.73M 3.29 N/A N/A N/A

Does the media favor PRVA or LMRI?

In the previous week, Privia Health Group and Privia Health Group both had 3 articles in the media. Privia Health Group's average media sentiment score of 1.77 beat Lumexa Imaging's score of 0.88 indicating that Privia Health Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Privia Health Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lumexa Imaging 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, HTFL or LMRI?

Lumexa Imaging has higher revenue and earnings than Heartflow. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Heartflow $176.03M 16.19 -$116.79M -$3.11 N/A Lumexa Imaging $267.73M 3.29 N/A N/A N/A

Is HTFL or LMRI more profitable?

Lumexa Imaging has a net margin of 0.00% compared to Heartflow's net margin of -58.42%. Company Net Margins Return on Equity Return on Assets Heartflow -58.42% N/A -20.02% Lumexa Imaging N/A N/A N/A

Which has stronger valuation and earnings, DFTX or LMRI?

Lumexa Imaging has higher revenue and earnings than Definium Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Definium Therapeutics N/A N/A -$183.79M -$2.49 N/A Lumexa Imaging $267.73M 3.29 N/A N/A N/A

Is DFTX or LMRI more profitable?

Lumexa Imaging's return on equity of 0.00% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Definium Therapeutics N/A -100.30% -69.22% Lumexa Imaging N/A N/A N/A

Does the media favor DFTX or LMRI?

In the previous week, Definium Therapeutics had 4 more articles in the media than Lumexa Imaging. MarketBeat recorded 7 mentions for Definium Therapeutics and 3 mentions for Lumexa Imaging. Lumexa Imaging's average media sentiment score of 0.88 beat Definium Therapeutics' score of 0.48 indicating that Lumexa Imaging is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lumexa Imaging 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lumexa Imaging (LMRI) Competitors

$9.15 -0.24 (-2.50%)

As of 12:09 PM Eastern

Compare

LMRI vs. LFST, GRAL, PRVA, HTFL, and DFTX

Should you buy Lumexa Imaging stock or one of its competitors? MarketBeat compares Lumexa Imaging with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lumexa Imaging include LifeStance Health Group (LFST), GRAIL (GRAL), Privia Health Group (PRVA), Heartflow (HTFL), and Definium Therapeutics (DFTX). These companies are all part of the "healthcare" industry.

How does Lumexa Imaging compare to LifeStance Health Group?

LifeStance Health Group (NASDAQ:LFST) and Lumexa Imaging (NASDAQ:LMRI) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

LifeStance Health Group has a net margin of 1.55% compared to Lumexa Imaging's net margin of 0.00%. LifeStance Health Group's return on equity of 1.56% beat Lumexa Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeStance Health Group	1.55%	1.56%	1.07%
Lumexa Imaging	N/A	N/A	N/A

In the previous week, LifeStance Health Group had 1 more articles in the media than Lumexa Imaging. MarketBeat recorded 4 mentions for LifeStance Health Group and 3 mentions for Lumexa Imaging. Lumexa Imaging's average media sentiment score of 0.88 beat LifeStance Health Group's score of 0.88 indicating that Lumexa Imaging is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeStance Health Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Lumexa Imaging	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LifeStance Health Group currently has a consensus price target of $9.75, indicating a potential upside of 12.52%. Lumexa Imaging has a consensus price target of $16.00, indicating a potential upside of 74.77%. Given Lumexa Imaging's higher possible upside, analysts clearly believe Lumexa Imaging is more favorable than LifeStance Health Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeStance Health Group	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.91
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

85.5% of LifeStance Health Group shares are owned by institutional investors. 6.6% of LifeStance Health Group shares are owned by insiders. Comparatively, 0.7% of Lumexa Imaging shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

LifeStance Health Group has higher revenue and earnings than Lumexa Imaging.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeStance Health Group	$1.42B	2.36	$9.66M	$0.06	144.42
Lumexa Imaging	$267.73M	3.29	N/A	N/A	N/A

Summary

LifeStance Health Group beats Lumexa Imaging on 10 of the 13 factors compared between the two stocks.

How does Lumexa Imaging compare to GRAIL?

GRAIL (NASDAQ:GRAL) and Lumexa Imaging (NASDAQ:LMRI) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

GRAIL presently has a consensus target price of $67.00, indicating a potential upside of 11.58%. Lumexa Imaging has a consensus target price of $16.00, indicating a potential upside of 74.77%. Given Lumexa Imaging's stronger consensus rating and higher probable upside, analysts plainly believe Lumexa Imaging is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRAIL	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Lumexa Imaging has a net margin of 0.00% compared to GRAIL's net margin of -253.22%. Lumexa Imaging's return on equity of 0.00% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRAIL	-253.22%	-16.42%	-14.34%
Lumexa Imaging	N/A	N/A	N/A

In the previous week, GRAIL had 37 more articles in the media than Lumexa Imaging. MarketBeat recorded 40 mentions for GRAIL and 3 mentions for Lumexa Imaging. Lumexa Imaging's average media sentiment score of 0.88 beat GRAIL's score of 0.01 indicating that Lumexa Imaging is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRAIL	3 Very Positive mention(s)	1 Positive mention(s)	30 Neutral mention(s)	0 Negative mention(s)	5 Very Negative mention(s)	Neutral
Lumexa Imaging	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lumexa Imaging has higher revenue and earnings than GRAIL.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRAIL	$147.17M	17.51	-$408.35M	-$10.37	N/A
Lumexa Imaging	$267.73M	3.29	N/A	N/A	N/A

Summary

Lumexa Imaging beats GRAIL on 8 of the 11 factors compared between the two stocks.

How does Lumexa Imaging compare to Privia Health Group?

Privia Health Group (NASDAQ:PRVA) and Lumexa Imaging (NASDAQ:LMRI) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Privia Health Group has a net margin of 0.97% compared to Lumexa Imaging's net margin of 0.00%. Privia Health Group's return on equity of 2.81% beat Lumexa Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Privia Health Group	0.97%	2.81%	1.61%
Lumexa Imaging	N/A	N/A	N/A

Privia Health Group currently has a consensus price target of $31.15, indicating a potential upside of 32.09%. Lumexa Imaging has a consensus price target of $16.00, indicating a potential upside of 74.77%. Given Lumexa Imaging's higher possible upside, analysts clearly believe Lumexa Imaging is more favorable than Privia Health Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Privia Health Group	0 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.79
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Privia Health Group and Privia Health Group both had 3 articles in the media. Privia Health Group's average media sentiment score of 1.77 beat Lumexa Imaging's score of 0.88 indicating that Privia Health Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Privia Health Group	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lumexa Imaging	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.5% of Privia Health Group shares are held by institutional investors. 5.7% of Privia Health Group shares are held by company insiders. Comparatively, 0.7% of Lumexa Imaging shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Privia Health Group has higher revenue and earnings than Lumexa Imaging.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Privia Health Group	$2.12B	1.40	$22.92M	$0.16	147.41
Lumexa Imaging	$267.73M	3.29	N/A	N/A	N/A

Summary

Privia Health Group beats Lumexa Imaging on 9 of the 12 factors compared between the two stocks.

How does Lumexa Imaging compare to Heartflow?

Heartflow (NASDAQ:HTFL) and Lumexa Imaging (NASDAQ:LMRI) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

In the previous week, Lumexa Imaging had 1 more articles in the media than Heartflow. MarketBeat recorded 3 mentions for Lumexa Imaging and 2 mentions for Heartflow. Lumexa Imaging's average media sentiment score of 0.88 beat Heartflow's score of -0.06 indicating that Lumexa Imaging is being referred to more favorably in the news media.

Company	Overall Sentiment
Heartflow	Neutral
Lumexa Imaging	Positive

Heartflow presently has a consensus target price of $37.00, indicating a potential upside of 11.95%. Lumexa Imaging has a consensus target price of $16.00, indicating a potential upside of 74.77%. Given Lumexa Imaging's stronger consensus rating and higher possible upside, analysts clearly believe Lumexa Imaging is more favorable than Heartflow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heartflow	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Lumexa Imaging has higher revenue and earnings than Heartflow.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heartflow	$176.03M	16.19	-$116.79M	-$3.11	N/A
Lumexa Imaging	$267.73M	3.29	N/A	N/A	N/A

Lumexa Imaging has a net margin of 0.00% compared to Heartflow's net margin of -58.42%.

Company	Net Margins	Return on Equity	Return on Assets
Heartflow	-58.42%	N/A	-20.02%
Lumexa Imaging	N/A	N/A	N/A

Summary

Lumexa Imaging beats Heartflow on 8 of the 10 factors compared between the two stocks.

How does Lumexa Imaging compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Lumexa Imaging (NASDAQ:LMRI) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

In the previous week, Definium Therapeutics had 4 more articles in the media than Lumexa Imaging. MarketBeat recorded 7 mentions for Definium Therapeutics and 3 mentions for Lumexa Imaging. Lumexa Imaging's average media sentiment score of 0.88 beat Definium Therapeutics' score of 0.48 indicating that Lumexa Imaging is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lumexa Imaging	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Definium Therapeutics presently has a consensus target price of $37.92, suggesting a potential upside of 59.68%. Lumexa Imaging has a consensus target price of $16.00, suggesting a potential upside of 74.77%. Given Lumexa Imaging's higher possible upside, analysts clearly believe Lumexa Imaging is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00
Lumexa Imaging	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

27.9% of Definium Therapeutics shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Comparatively, 0.7% of Lumexa Imaging shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lumexa Imaging has higher revenue and earnings than Definium Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A
Lumexa Imaging	$267.73M	3.29	N/A	N/A	N/A

Lumexa Imaging's return on equity of 0.00% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-100.30%	-69.22%
Lumexa Imaging	N/A	N/A	N/A

Summary

Definium Therapeutics beats Lumexa Imaging on 6 of the 11 factors compared between the two stocks.

Get Lumexa Imaging News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LMRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LMRI vs. The Competition

Export

Metric	Lumexa Imaging	Services – Health Industry	Services Sector	NASDAQ Exchange
Market Cap	$879.61M	$1.84B	$980.02M	$12.26B
Dividend Yield	N/A	N/A	4.72%	5.66%
P/E Ratio	N/A	16.76	11.47	24.45
Price / Sales	3.29	5.93	39.51	138.25
Price / Cash	N/A	161.84	55.62	37.92
Price / Book	N/A	37.24	11.60	6.73
Net Income	N/A	-$33.67M	-$12.34M	$337.21M
7 Day Performance	5.84%	3.11%	5.16%	2.03%
1 Month Performance	30.23%	6.42%	1.39%	3.90%
1 Year Performance	N/A	N/A	63.60%	28.85%

Lumexa Imaging Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LMRI Lumexa Imaging	4.4707 of 5 stars	$9.16 -2.5%	$16.00 +74.8%	N/A	$879.61M	$267.73M	N/A	4,335
LFST LifeStance Health Group	4.2779 of 5 stars	$7.64 +1.9%	$9.86 +29.0%	+63.3%	$2.91B	$1.42B	127.33	10,961	Analyst Downgrade
GRAL GRAIL	2.8816 of 5 stars	$66.55 +8.9%	$67.88 +2.0%	+44.8%	$2.62B	$147.17M	N/A	1,360	Trending News Gap Down
PRVA Privia Health Group	4.427 of 5 stars	$21.37 +3.4%	$31.15 +45.8%	+1.6%	$2.60B	$2.12B	133.57	1,226	Positive News
HTFL Heartflow	2.051 of 5 stars	$28.80 -0.2%	$37.00 +28.5%	N/A	$2.49B	$176.03M	N/A	699

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LMRI) was last updated on 6/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lumexa Imaging (LMRI) Competitors

LMRI vs. LFST, GRAL, PRVA, HTFL, and DFTX

How does Lumexa Imaging compare to LifeStance Health Group?

Summary

How does Lumexa Imaging compare to GRAIL?

Summary

How does Lumexa Imaging compare to Privia Health Group?

Summary

How does Lumexa Imaging compare to Heartflow?

Summary

How does Lumexa Imaging compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LMRI vs. The Competition

Lumexa Imaging Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lumexa Imaging (LMRI) Competitors

LMRI vs. LFST, GRAL, PRVA, HTFL, and DFTX

How does Lumexa Imaging compare to LifeStance Health Group?

Is LFST or LMRI more profitable?

Does the media refer more to LFST or LMRI?

Do analysts prefer LFST or LMRI?

Do insiders & institutionals believe in LFST or LMRI?

Which has stronger earnings and valuation, LFST or LMRI?

Summary

How does Lumexa Imaging compare to GRAIL?

Do analysts prefer GRAL or LMRI?

Is GRAL or LMRI more profitable?

Does the media favor GRAL or LMRI?

Which has better valuation and earnings, GRAL or LMRI?

Summary

How does Lumexa Imaging compare to Privia Health Group?

Is PRVA or LMRI more profitable?

Do analysts prefer PRVA or LMRI?

Does the media favor PRVA or LMRI?

Do institutionals & insiders believe in PRVA or LMRI?

Which has higher valuation & earnings, PRVA or LMRI?

Summary

How does Lumexa Imaging compare to Heartflow?

Does the media refer more to HTFL or LMRI?

Do analysts rate HTFL or LMRI?

Which has higher earnings and valuation, HTFL or LMRI?

Is HTFL or LMRI more profitable?

Summary

How does Lumexa Imaging compare to Definium Therapeutics?

Does the media favor DFTX or LMRI?

Do analysts recommend DFTX or LMRI?

Do institutionals & insiders have more ownership in DFTX or LMRI?

Which has stronger valuation and earnings, DFTX or LMRI?

Is DFTX or LMRI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LMRI vs. The Competition

Lumexa Imaging Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools